Esperion Therapeutics (ESPR) Enterprise Value: 2018-2025
Historic Enterprise Value for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $441.9 million.
- Esperion Therapeutics' Enterprise Value rose 146.77% to $441.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.4 million, marking a year-over-year increase of 130.21%. This contributed to the annual value of $288.7 million for FY2024, which is 12.01% up from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Enterprise Value is $441.9 million, which was up 305.20% from $109.0 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Enterprise Value registered a high of $565.9 million during Q1 2021, and its lowest value of -$113.9 million during Q4 2021.
- In the last 3 years, Esperion Therapeutics' Enterprise Value had a median value of $179.1 million in 2024 and averaged $171.8 million.
- Per our database at Business Quant, Esperion Therapeutics' Enterprise Value plummeted by 155.61% in 2023 and then skyrocketed by 3,491.76% in 2024.
- Esperion Therapeutics' Enterprise Value (Quarterly) stood at -$113.9 million in 2021, then soared by 356.43% to $292.2 million in 2022, then fell by 11.78% to $257.8 million in 2023, then grew by 12.01% to $288.7 million in 2024, then skyrocketed by 146.77% to $441.9 million in 2025.
- Its Enterprise Value was $441.9 million in Q3 2025, compared to $109.0 million in Q2 2025 and $170.3 million in Q1 2025.